Estifanos Baye

Estifanos Baye

Auto-generated profile, based on publicly available information

Estifanos Baye

Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, 43-51 Kanooka Grove, Clayton, Melbourne, VIC, 3168, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Fertility and Sterility
Verified
Journal Article
Open access
HTHelena Jane Teede
Helena Jane Teede
MMMarie L. Misso
Marie L. Misso
MCMichael F. Costello
Michael F. Costello
ADAnuja Dokras
Anuja Dokras
JLJoop Laven
Joop Laven
BYBulent O. Yildiz
Bulent O. Yildiz
What is the recommended assessment and management of women with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? International evidence-based guidelines including 166 recommendations and practice points, addressed prioritized questions to promote consistent, evidence-based care and improve the experience and health outcomes of women with PCOS. Previous guidelines either lacked rigorous evidence-based processes, did not engage consumer and international multidisciplinary perspectives, or were outdated. Diagnosis of PCOS remains controversial and assessment and management are inconsistent. The needs of women with PCOS are not being adequately met and evidence practice gaps persist. International evidence-based guideline development engaged professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Appraisal of Guidelines for Research and Evaluation (AGREE) II-compliant processes were followed, with extensive evidence synthesis. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength. Governance included a six continent international advisory and a project board, five guideline development groups, and consumer and translation committees. Extensive health professional and consumer engagement informed guideline scope and priorities. Engaged international society-nominated panels included pediatrics, endocrinology, gynecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, public health and other experts, alongside consumers, project management, evidence synthesis, and translation experts. Thirty-seven societies and organizations covering 71 countries engaged in the process. Twenty face-to-face meetings over 15 months addressed 60 prioritized clinical questions involving 40 systematic and 20 narrative reviews. Evidence-based recommendations were developed and approved via consensus voting within the five guideline panels, modified based on international feedback and peer review, with final recommendations approved across all panels. The evidence in the assessment and management of PCOS is generally of low to moderate quality. The guideline provides 31 evidence based recommendations, 59 clinical consensus recommendations and 76 clinical practice points all related to assessment and management of PCOS. Key changes in this guideline include: i) considerable refinement of individual diagnostic criteria with a focus on improving accuracy of diagnosis; ii) reducing unnecessary testing; iii) increasing focus on education, lifestyle modification, emotional wellbeing and quality of life; and iv) emphasizing evidence based medical therapy and cheaper and safer fertility management. Overall evidence is generally low to moderate quality, requiring significantly greater research in this neglected, yet common condition, especially around refining specific diagnostic features in PCOS. Regional health system variation is acknowledged and a process for guideline and translation resource adaptation is provided. The international guideline for the assessment and management of PCOS provides clinicians with clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports the guideline with an integrated evaluation program. The guideline was primarily funded by the Australian National Health and Medical Research Council of Australia (NHMRC) supported by a partnership with ESHRE and the American Society for Reproductive Medicine. Guideline development group members did not receive payment. Travel expenses were covered by the sponsoring organizations. Disclosures of conflicts of interest were declared at the outset and updated throughout the guideline process, aligned with NHMRC guideline processes. Full details of conflicts declared across the guideline development groups are available at https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline in the Register of disclosures of interest. Of named authors, Dr Costello has declared shares in Virtus Health and past sponsorship from Merck Serono for conference presentations. Prof. Laven declared grants from Ferring, Euroscreen and personal fees from Ferring, Euroscreen, Danone and Titus Healthcare. Prof. Norman has declared a minor shareholder interest in an IVF unit. The remaining authors have no conflicts of interest to declare. The guideline was peer reviewed by special interest groups across our partner and collaborating societies and consumer organizations, was independently assessed against AGREEII criteria and underwent methodological review. This guideline was approved by all members of the guideline development groups and was submitted for final approval by the NHMRC.

1 June 2017 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
TCThe Global Burden of Disease Child
The Global Burden of Disease Child
ACAdolescent Health Collaboration
Adolescent Health Collaboration
NKNicholas Kassebaum
Nicholas Kassebaum
HKHmwe Hmwe Kyu
Hmwe Hmwe Kyu
LZLeo Zoeckler
Leo Zoeckler
TVTheo Vos
Theo Vos
Reducing mortality among children younger than 5 years has been a focus of significant international attention for several decades, beginning with the Convention on the Rights of the Child, accelerating during the Millennium Development Goal era, and continuing with the Sustainable Development Goals (SDGs).1-3 Global progress in reducing death in children younger than 5 years has been substantial,4 but much less attention has been focused on quantifying and minimizing mortality burden among older children and adolescents.5 Likewise, nonfatal health outcomes have received comparatively little attention despite the fact that injuries, noncommunicable diseases (NCDs), and acquired chronic conditions with childhood onset profoundly affect long-term health trajectories, future health care needs, intellectual development, and economic and productivity prospects.6-8

23 May 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EBEstifanos Baye
Estifanos Baye
VKVelislava Kiriakova
Velislava Kiriakova
JUJaime Uribarri
Jaime Uribarri
LMLisa J Moran
Lisa J Moran
Barbora de CourtenBarbora de Courten
Barbora de Courten
Studies examining the effects of consumption of diets low in advanced glycation end products (AGEs) on cardiometabolic parameters are conflicting. Hence, we performed a meta-analysis to determine the effect of low AGE diets in reducing cardiometabolic risk factors. Seventeen randomised controlled trials comprising 560 participants were included. Meta-analyses using random effects models were used to analyse the data. Low AGE diets decreased insulin resistance (mean difference [MD] −1.3, 95% CI −2.3, −0.2), total cholesterol (MD −8.5 mg/dl, 95% CI −9.5, −7.4) and low-density lipoprotein (MD −2.4 mg/dl, 95% CI −3.4, −1.3). There were no changes in weight, fasting glucose, 2-h glucose and insulin, haemoglobin A1c, high-density lipoprotein or blood pressure. In a subgroup of patients with type 2 diabetes, a decrease in fasting insulin (MD −7 µU/ml, 95% CI −11.5, −2.5) was observed. Tumour necrosis factor α, vascular cell adhesion molecule-1, 8-isoprostane, leptin, circulating AGEs and receptor for AGEs were reduced after consumption of low AGE diets with increased adiponectin and sirtuin-1. Our findings suggest that diets low in AGEs may be an effective strategy for improving cardiometabolic profiles in individuals with and without type 2 diabetes.

16 March 2016 in Amino Acids
Verified
Journal Article
Closed access
PDF file
EBEstifanos Baye
Estifanos Baye
BUBarbara Ukropcová
Barbara Ukropcová
JUJozef Ukropec
Jozef Ukropec
AHAlan Hipkiss
Alan Hipkiss
GAGiancarlo Aldini
Giancarlo Aldini
Barbora de CourtenBarbora de Courten
Barbora de Courten

1 November 2016 in Maturitas
Verified
Journal Article
Closed access
AHAlan HIpkiss
Alan HIpkiss
EBEstifanos Baye
Estifanos Baye
Barbora de CourtenBarbora de Courten
Barbora de Courten

7 March 2018 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
YMYohannes Adama Melaku
Yohannes Adama Melaku
ARAndre Renzaho
Andre Renzaho
TGTiffany K. Gill
Tiffany K. Gill
ATAnne Taylor
Anne Taylor
EGEleonora Dal Grande
Eleonora Dal Grande
YKYohannes Kinfu
Yohannes Kinfu